HeartBeam

HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. Its electrocardiogram (ECG) collection device provides physicians with cardiac diagnostic information for a patient that is outside of a medical institution. The device sends ECG signals to the patient's smartphone and on to a cloud-based software expert system. The company was founded by Branislav Vajdic in 2015 and is headquartered in Santa Clara, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

HeartBeam reports Q1 loss, eyes FDA clearances for growth

HeartBeam's Q1 2024 performance showed financial challenges but promising technological advancements
The company's focus on FDA clearances and AI development positions it for growth
Opportunities in remote cardiac monitoring and AI-driven healthcare present avenues for expansion
Balancing financial stability with innovation will be key for HeartBeam's future success

HeartBeam advances AIMIGo technology despite financial challenges

HeartBeam is making progress towards FDA clearance for its innovative cardiac monitoring device, AIMIGo.
Despite financial challenges, the company's strong IP protection and AI capabilities position it well for future growth.
Opportunities lie in expanding technology applications, gaining regulatory approval, and leveraging AI for automated diagnostics.

HeartBeam reports Q3 loss, progresses FDA review, and strengthens leadership

HeartBeam's Q3 2024 financials show a net loss of $4.979 million, with a focus on managing cash burn and aligning capital raising with milestones.
The company's core technology and clinical evidence position it well for FDA clearances and commercial launch preparations.
New management appointments bring leadership strength to drive HeartBeam's growth and innovation in cardiac care.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioTelemetry's (BEAT) CEO Joseph Capper on Q2 2020 Results - Earnings Call Transcript

BioTelemetry (BEAT) delivered earnings and revenue surprises of 191.67% and 15.34%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

BioTelemetry (BEAT) Beats Q2 Earnings and Revenue Estimates

Posts Strong Results and Ramps Up Business Development Activity Posts Strong Results and Ramps Up Business Development Activity

BioTelemetry, Inc. Reports Second Quarter 2020 Financial Results

Company expands portfolio of solutions with groundbreaking insertable cardiac monitor system Company expands portfolio of solutions with groundbreaking insertable cardiac monitor system

BioTelemetry, Inc. Announces  Sales Agent Agreement with Boston Scientific Corporation

Expands relationship to serve Centene members Expands relationship to serve Centene members

BioTelemetry, Inc. Acquires Remote Patient Monitoring Platform from Centene Subsidiary

MALVERN, Pa., July  23, 2020  (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its second quarter 2020 earnings on Thursday, July 30 at 4:00 PM Eastern Time.

BioTelemetry, Inc. to Release Second Quarter 2020 Earnings Results on July 30, 2020

BioTelemetry: Still Undervalued Despite Pandemic Headwinds

BioTelemetry, Inc. (BEAT) CEO Joseph Capper on Q1 2020 Results - Earnings Call Transcript

BioTelemetry (BEAT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for BioTelemetry (BEAT) This Earnings Season?

BioTelemetry (BEAT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioTelemetry (BEAT) to Report Q1 Results: Wall Street Expects Earnings Growth

MALVERN, Pa., April  07, 2020  (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that Dr. Andrei Stoica has been named Chief Technology Officer of the company.  Dr. Stoica will lead the company’s global technology and product development operations, reporting to Joseph H. Capper, President and Chief Executive Officer.

BioTelemetry, Inc. Names Dr. Andrei Stoica  Chief Technology Officer

Only remote cardiac monitoring company whose proprietary connected system has FDA-approved indication to measure, analyze and report QT interval Only remote cardiac monitoring company whose proprietary connected system has FDA-approved indication to measure, analyze and report QT interval

BIOTELEMETRY, INC. EXPANDS MCOT™ SERVICE TO MONITOR LIFE-THREATENING QT PROLONGATION IN COVID-19 PATIENTS

BioTelemetry, Inc. (BEAT) CEO Joseph Capper on Q4 2019 Results - Earnings Call Transcript

BioTelemetry (BEAT) delivered earnings and revenue surprises of 0.00% and 1.53%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

BioTelemetry (BEAT) Q4 Earnings Meet Estimates

BioTelemetry (BEAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: BioTelemetry (BEAT) Q4 Earnings Expected to Decline

BioTelemetry: I Foresee Further Share Price Growth Going Into New Year

AbbVie

Axalta Coating Systems

Associated Capital Group

Advanced Disposal Services

Cars.com

Globus Medical

IntriCon

CFA, Chairman andCEO of GAMCO Investors, Inc., Mario Gabelli (Trades, Portfolio), bought shares of the following stocks in both the second and third quarters.

Mario Gabelli Continues to Buy AbbVie, Axalta

BioTelemetry's (BEAT) CEO Dave Bauer on Q3 2019 Results - Earnings Call Transcript

BioTelemetry (BEAT) delivered earnings and revenue surprises of 4.00% and 0.28%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

BioTelemetry (BEAT) Beats Q3 Earnings and Revenue Estimates

MALVERN, Pa., Sept.  03, 2019  (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today it has been ranked 31st on Fortune Magazine’s 100 Fastest-Growing Companies list for 2019. The ranking is based on the combination of revenue growth, earnings growth and the three-year annualized total return. It applies to U.S. publicly traded companies.

BioTelemetry, Inc. Named to Fortune Magazine’s 100 Fastest-Growing Companies List

Apple's Heart Study disruption continues as the Apple Watch maintains strong growth along with services.

BioTelemetry: A Strong Buy At 52-Week Lows As A Key Part Of Apple's Heart Study Innovation

BioTelemetry Inc. (BEAT) CEO Joseph Capper on Q2 2019 Results - Earnings Call Transcript

BioTelemetry (BEAT) delivered earnings and revenue surprises of 17.78% and 0.65%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

BioTelemetry (BEAT) Q2 Earnings and Revenues Beat Estimates

Analysts Estimate BioTelemetry (BEAT) to Report a Decline in Earnings: What to Look Out for

BioTelemetry's (BEAT) strong second-quarter 2019 expectations are indicative of solid results.

News for HeartBeam Stock (BEAT)